

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/545, 33/535		A1	(11) International Publication Number: WO 97/07398 (43) International Publication Date: 27 February 1997 (27.02.97)
(21) International Application Number: PCT/US96/13057 (22) International Filing Date: 9 August 1996 (09.08.96)		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/514,075 11 August 1995 (11.08.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant: DADE INTERNATIONAL INC. [US/US]; 1717 Deerfield Road, Deerfield, IL 60015 (US).			
(72) Inventor: SINGH, Pratap; 15111 S.W. 69th Street, Miami, FL 33193 (US).			
(74) Agents: WINSTON, Lois, K. et al.; 1717 Deerfield Road, Deerfield, IL 60015 (US).			

(54) Title: POLYPEPTIDE-DENDRIMER COMPLEXES

(57) Abstract

Compositions are disclosed, comprising dendrimers to which a first polypeptide is controllably coupled. Such polypeptide-dendrimer compositions are effective for controllably coupling a second polypeptide to the dendrimer. The first and second polypeptides have separate and distinct defined biological activities, for example, two antibodies with first and second binding specificities or an antibody and an enzymatic label. Such compositions are useful as indicators in specific binding assays, e.g., immunoassays. Methods for sequentially coupling two different polypeptides to a dendrimer to form compositions of the invention also are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

Polypeptide:Dendrimer Complexes

5

Field of the Invention

This invention relates generally to compositions comprising a first polypeptide coupled to a dendrimer and, optionally, a second polypeptide coupled to the same dendrimer. The invention also relates to methods for 10 coupling a first polypeptide and, optionally, a second polypeptide to a dendrimer.

Background of the Invention

Dendrimers are polymers of spherical or other three-dimensional shapes that have precisely defined 15 compositions and that possess a precisely defined molecular weight. Dendrimers can be synthesized as water soluble macromolecules through appropriate selection of internal and external moieties. See U.S. Patent Nos. 4,507,466 and 4,568,737, incorporated by reference 20 herein. Starburst[™] dendrimers are manufactured by The Dow Chemical Company.

Dendrimers have been conjugated with various pharmaceutical materials as well as with various targeting molecules that may function to direct the 25 conjugates to selected body locations for diagnostic or therapeutic applications. See for example, WO 8801178, incorporated by reference herein. Dendrimers have been used to covalently couple synthetic porphyrins (e.g., hemes, chlorophyll) to antibody molecules as a means for 30 increasing the specific activity of radiolabeled antibodies for tumor therapy and diagnosis. Roberts, J.C. et al., Using Starburst Dendrimers as Linker

- 2 -

Molecules to Radiolabel Antibodies, Bioconjug. Chemistry
1:305-308 (1990).

It is known to directly covalently couple two different polypeptides, e.g., to form a conjugated reagent for a diagnostic assay. Polypeptide-polypeptide conjugates, although useful, have a number of disadvantages. The conjugation reaction is often relatively uncontrolled, leading to intermolecular conjugation of the two polypeptides at more sites on each polypeptide than is desired, intermolecular conjugation of two molecules of the same polypeptide, and even intramolecular conjugation within the same polypeptide molecule. The proportion of each species may vary in each production lot, resulting in variability in titer, purity, specificity and specific activity. In a solid phase diagnostic assay, certain of these species may lead to high non-specific binding and decreased assay sensitivity. Numerous and costly quality control and standardization procedures may be required when manufacturing such conjugates.

Moreover, variability in the shelf life of such conjugated polypeptide reagents may be encountered due to the tendency of such conjugates to become inhomogeneously distributed within stock solutions. That is, such conjugates, while substantially soluble, may not remain completely soluble and may undergo some settling out of solution over time. Even with periodic mixing of stock solutions, gravitational influences, temperature gradients and other physical influences can cause inhomogeneities.

Dendrimer: antibody complexes have been used to form assay reagents that overcome some of the problems of polypeptide-polypeptide conjugates. The dendrimer portion of such complexes is used to facilitate immobilization of assay reagents on a solid phase. For example, antibodies have been attached to dendrimers by

- 3 -

the formation of carbon-sulfur (C-S) linkages between a dendrimer derivatized with sulfosuccinimidyl-(4-iodoacetyl) aminobenzoate (sulfo-SIAB) and a sulfhydryl group on an antibody. See U.S. Patent Application Serial

5 No. 08/021,928, incorporated by reference herein.

Known dendrimer-coupled antibodies have a very strong affinity for the glass fiber solid phase (tab) used in such immunoassays. U.S. Patent Application Serial No. 08/021,928 incorporated by reference herein; U.S. Patent

10 Application Serial No. 08/222,172, incorporated by reference herein. In the spotting buffer (pH 8.0), the tab has a net negative charge whereas the dendrimer-antibody complex has a net positive charge, due to the presence of a very large number of free amino groups.

15 The charge interaction between the dendrimer-antibody and glass fiber solid phase can be so strong as to localize the dendrimer-coupled antibody at the point of application on the solid phase.

Summary of the Invention

20 Dendrimer/polypeptide complexes are disclosed herein. These complexes comprise a dendrimer having a plurality of termini, a first polypeptide and a second polypeptide. The first polypeptide and the second polypeptide are sequentially coupled to the dendrimer via its termini.

25 The first and second polypeptides of the complex exhibit first and second defined biological activities, respectively. Alternatively, a dendrimer/polypeptide complex may comprise a dendrimer coupled to a first polypeptide exhibiting a first defined biological

30 activity and at least one terminus on the dendrimer to which a second polypeptide, possessing a second defined biological activity, may be coupled. Some fraction of the termini in dendrimer/polypeptide complexes may be uncoupled. Uncoupled termini may be blocked, if desired.

- 4 -

Dendrimers useful according to the invention include, without limitation, first, second, third, fourth, and fifth generation ethylenediamine core dendrimers. Alternatively, the dendrimer may be a first, second, 5 third, fourth, or fifth half-generation ethylenediamine core dendrimer.

One of the defined biological activities may comprise, for example, enzymatic catalysis. Such enzymatic catalysis may comprise formation of a fluorescent, 10 colorimetric, chemiluminescent, phosphorescent, radiometric or hybridized product after contact with a substrate. Polypeptides exhibiting such enzymatic catalysis may be, for example, alkaline phosphatase, β -galactosidase, glucose oxidase, peroxidase, urease, 15 catalase, adenosine deaminase, glycosidase, protease, esterase, DNase, RNase and acetylcholinesterase.

Another suitable defined biological activity may comprise specific binding to an analyte or receptor for the analyte. A polypeptide having such a specific 20 binding activity may comprise, for example, an antibody or antibody fragment having specificity for creatine kinase isozyme MB, troponin I, myoglobin, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone or ferritin.

25 A method of making a polypeptide/dendrimer complex is disclosed herein. The method comprises the steps of providing a dendrimer comprising a plurality of activated termini, providing a first polypeptide having at least one reactive moiety and coupling the first polypeptide via the reactive moiety to one of the activated termini. The method forms a polypeptide/dendrimer complex that 30 exhibits a first defined biological activity possessed by the first polypeptide. Such a complex is adapted for coupling a second polypeptide, possessing a second 35 defined biological activity, to the dendrimer.

- 5 -

The dendrimer used in such a method may be a first, second, third, fourth, or fifth generation ethylenediamine core dendrimer. The reactive moiety on the polypeptide may comprise a sulfhydryl group and the 5 activated terminus may comprise an iodoacetyl group. The dendrimer in such a method may also be a first, second, third, fourth or fifth half generation ethylenediamine core dendrimer. For such dendrimers, the reactive moiety on the polypeptide may comprise an amino group and the 10 activated terminus may comprise an N-hydroxysuccinimidyl group.

The method may further comprise the steps of: providing a second polypeptide having at least one reactive moiety and coupling the second polypeptide via the reactive 15 moiety to one of the activated termini to form a two polypeptide/dendrimer complex. The second polypeptide possesses a second defined biological activity and the resulting complex exhibits both the first and the second defined biological activities. For this method, both the 20 first polypeptide and the second polypeptide reactive moieties may comprise sulfhydryl groups and the plurality of activated termini may comprise iodoacetyl, bromoacetyl, chloroacetyl, epoxy or maleimide groups.

Alternatively, when at least one of the activated 25 termini in the first polypeptide/dendrimer complex is uncoupled, the method may further comprise the steps of activating one or more of the uncoupled termini of the complex with a second activating group, providing a second polypeptide having a reactive moiety and 30 possessing a second defined biological activity and coupling a second polypeptide reactive moiety to a second activated terminus to form a two polypeptide/dendrimer complex. Such a complex exhibits both the first and the second defined biological activities of the first and 35 second polypeptides, respectively. For such methods, the

- 6 -

first polypeptide reactive moiety may comprise an amino group, the second polypeptide reactive moiety may comprise a sulfhydryl group, the plurality of activated termini may comprise N-hydroxysuccinimidyl groups and the 5 second activated terminus may comprise a bromoacetyl iodoacetyl, chloroacetyl, epoxy or maleimidyl group.

Brief Description of the Drawings

Figure 1 shows the absorbance at 280 nanometers (A_{280}) of column fractions of an ALP-E1-Fab' 10 polypeptide:dendrimer complex eluted from an Ultrogel AcA-34 column.

Figure 2 shows the A_{280} of column fractions of an ALP-E2-Fab' polypeptide:dendrimer complex eluted from an Ultrogel AcA-34 column.

15 Figure 3 shows the A_{280} of column fractions of an ALP-E3-Fab' polypeptide:dendrimer complex eluted from an Ultrogel AcA-34 column.

Figure 4 shows the A_{280} of column fractions of an ALP-E4-Fab' polypeptide:dendrimer complex eluted from an 20 Ultrogel AcA-34 column.

Figure 5 shows the A_{280} of column fractions of an ALP-E5-Fab' polypeptide:dendrimer complex eluted from an Ultrogel AcA-34 column.

Description of the Preferred Embodiments

25 The applicants have made the surprising discovery that two different polypeptides, having separate and distinct biological activities, can be sequentially coupled to the same dendrimer such that the polypeptide:dendrimer ratio for each polypeptide in a composition is readily

- 7 -

controlled and the native biological activity of each polypeptide is substantially retained.

Compositions according to the invention comprise a first polypeptide attached to at least one terminal 5 branch of a dendrimer, which polypeptide possesses a first defined biological activity. Certain compositions may further comprise a second polypeptide, possessing a second defined biological activity and coupled to the same dendrimer.

10 Dendrimers useful in preparing compositions of the present invention are generally spherical branched polymers having "star" configurations as disclosed in U.S. Patent No. 4,507,466. Star configuration dendrimers possess a structured branching wherein individual 15 branches radiate out from a nucleus, or core region. The polyvalent core is covalently bonded to at least two ordered dendritic (tree-like) branches that extend through one or more tiers, or generations. The outermost tier or generation terminates in functional groups that 20 may be chemically reactive with a variety of other molecules. Thus, star dendrimers are unitary molecular assemblages that possess three distinguishing architectural features, namely (a) an initiator core, (b) interior layers (generations) composed of repeating units 25 radially attached to the initiator core, and (c) an exterior surface of activated functional groups attached to the outermost, or terminal, ends of each branch. The size, shape and reactivity of a dendrimer can be controlled by the choice of the initiator core, the 30 number of generations employed in creating the dendrimer, and the choice of the repeating units employed at each generation. Dendrimers of discrete sizes are readily obtained as the number of generations employed increases. Generally spherical dendrimers of configurations suitable 35 for use in the present invention are disclosed in U.S.

- 8 -

Patent No. 4,507,466 and U.S. Patent No. 4,568,737, incorporated herein by reference. Alternatively, dendrimers of non-spherical configuration, such as those disclosed in U.S. Patent No. 4,694,064, incorporated 5 herein by reference, may be adapted for use in the present invention. Dendrimers to be used in the present invention preferably are first through fifth generation dendrimers.

Chemical modification of all or a portion of the 10 dendrimer termini creates surface functionalities appropriate for a particular application. Dendrimers to be used in compositions according to the present invention have a functionalized group linked to one or more termini. For example, an E5 dendrimer is a fifth- 15 generation, ethylenediamine core particle having 128 amine-terminated end (surface) groups and a molecular weight of 28,826. Similarly, an E2 dendrimer contains 16 termini, each carrying an amino group. The amine- terminated end groups impart a net positive charge to the 20 surfaces of such dendrimers in a solution of neutral pH. As another example, a G(4½) half-generation dendrimer is a fifth generation, ethylenediamine core particle in which the carboxymethyl ester termini of the fifth 25 generation intermediate are not converted to amino groups as the final step, but rather are converted to carboxyl groups by hydrolysis, thereby creating a molecule having 128 terminal carboxyl groups. Similarly, a G(1½)-COOH half-generation dendrimer has 16 carboxyl-terminated ends. The carboxyl-terminated end groups impart a net 30 negative charge to the surfaces of such dendrimers in a solution of neutral pH.

Polypeptides suitable for the invention include, without limitation, antibodies, antibody fragments, binding proteins, enzymes, peptide hormones and peptides 35 with certain repetitive sequences for specific

- 9 -

recognition. A polypeptide to be coupled to a dendrimer may be an oligopeptide in certain embodiments. In other embodiments, a polypeptide may comprise one subunit of a multisubunit protein which, after coupling, may be
5 suitable for interacting with remaining uncoupled subunits to reconstitute an intact, functional protein. In some embodiments, a polypeptide may have associated cofactors or metal ion ligands that are not involved in coupling to a dendrimer but are important for biological
10 activity of the polypeptide.

In compositions according to the invention, the average number of first polypeptide molecules coupled to a dendrimer molecule (polypeptide:dendrimer ratio) may be from about 0.1 to about 10, but typically is from about
15 0.2 to about 2.0. It is apparent that higher generation dendrimers may have higher polypeptide:dendrimer ratios than lower generation dendrimers and, therefore, appropriate choice of dendrimer generation will assist in attaining a desired polypeptide: dendrimer ratio.

20 The average number of dendrimer termini that are involved in polypeptide coupling may be adjusted by varying reaction conditions, for example, reaction time, pH and the like. A dendrimer-polypeptide composition typically does not have all terminal end groups involved
25 in polypeptide coupling. Termini that are not involved in polypeptide coupling may be converted to another form, if desired, e.g., by blocking remaining uncoupled termini with hydroxyl, alkyl, aryl, amide, nitrile, ether, thioether, or blocked sulfhydryl groups. For example,
30 replacement of uncoupled terminal groups with uncharged terminal groups is advantageous in those cases where a net charge on the composition adversely affects the useful properties of the composition for its intended end use. Blocking of uncoupled terminal may require a

- 10 -

separate blocking step, or may occur during the coupling step.

A first polypeptide possesses a first biological activity. Typical biological activities possessed by a 5 polypeptide include, without limitation, specific binding to an analyte or receptor for an analyte, specific binding to cell walls or membranes, enzymatic catalysis, direct or indirect detection of a substrate, electrical charge transfer capabilities, specific dielectric 10 constants and specific tertiary conformations that are assumed under a specified set of conditions.

A composition according to the invention may further comprise a second polypeptide coupled to a dendrimer:first polypeptide complex. If one or more 15 second polypeptide molecules are present in a composition, the biological activity of the second polypeptide is distinct from the first polypeptide, i.e., the two polypeptides do not possess the same biological activity. However, it is recognized that in certain 20 embodiments, both polypeptides may have the same general function but with differing specificities. For example, both polypeptides may be antibodies, each antibody recognizing separate and distinct epitopes. The two epitopes may be on the same or on a different molecule. 25 In other embodiments, both polypeptides may be enzymes, each enzyme having a separate and distinct catalytic activity. Such embodiments are within the scope of the invention.

If a composition further comprises a second 30 polypeptide, the polypeptide:dendrimer ratio for each polypeptide may be different, if desired, e.g., a first polypeptide may be present in a composition at a ratio of about 1:1 and a second polypeptide may be present at a ratio of about 3:1. In this case, the first 35 polypeptide:second polypeptide ratio is about 0.33. Such

- 11 -

ratios may be controllably varied to achieve a desired specific biological activity value per mole of dendrimer for each polypeptide.

The desired polypeptides are selected based on the end
5 use of the dendrimer-polypeptide composition. In a preferred embodiment, one of the polypeptides is an antibody, antibody fragment, or specific binding protein and the other polypeptide is an enzyme that produces a fluorescent, colorimetric, chemiluminescent,
10 phosphorescent, or radiometric product after contact with a substrate.

A method of controllably coupling a polypeptide to a dendrimer comprises incubating a selected generation of dendrimer containing at least one activated terminal
15 group with a polypeptide containing at least one reactive moiety. Dendrimers useful according to the invention have at least one activated terminal group suitable for coupling a terminal group to a reactive moiety on a polypeptide. Dendrimer termini are activated by reaction
20 of a heterobifunctional reagent with existing terminal groups. The reaction, carried out under mild conditions, does not affect characteristic structural features of the dendrimer. Controllably coupling a polypeptide to a dendrimer involves reacting an activated dendrimer
25 terminal group with a reactive moiety on a polypeptide. Activated termini are useful for accelerating the reaction rate when coupling a polypeptide to a dendrimer. It is preferable for substantially all of the terminal groups of the dendrimer to be activated. By
30 substantially all is meant at least 90% of the terminal groups of the dendrimer, preferably at least about 95%, more preferably at least about 99%. However, a dendrimer may have a portion of its terminal groups activated and the remainder of its terminal groups unactivated in
35 certain embodiments.

- 12 -

Polypeptides typically are coupled to a dendrimer by the formation of carbon-nitrogen (C-N) linkages, carbon-oxygen (C-O) linkages, or carbon-sulfur (C-S) linkages.

Amino groups on dendrimer termini are known to be

5 suitable for coupling to reactive carboxyl groups on polypeptides to form C-N linkages. A suitable reactive group with which to functionalize dendrimer terminal groups is an electrophilic group such as an iodoacetamido moiety. An iodoacetamido group can be introduced onto an

10 amino terminus of a dendrimer under mild reaction conditions by treatment of an amine-containing species with an activated ester (e.g., N-hydroxysuccinimidyl esters) of a iodoacetamido-containing molecule. A number of commercial products are available for this purpose,

15 e.g., N-hydroxysuccinimidyl iodoacetamide (NIA, available from, for example, BioAffinity Systems, Inc. Roscoe, IL). However, N-hydroxysuccinimidyl esters having a hydrophobic aromatic spacer group (e.g., phenyl) are not preferred, because of decreased solubility when a large

20 number of hydrophobic groups are introduced into polypeptide:dendrimer complexes of the present invention.

A preferred group for activating carboxylated dendrimer termini is N,N,N',N'-tetramethyl (succinimido)uronium tetrafluoroborate (TSTU). This reagent converts a

25 carboxyl group to an activated N-hydroxysuccinimidyl (NHS) ester and is preferred because it allows purification and quantitation of the NHS esterified dendrimer formed during this reaction. This activated dendrimer can be reacted directly with a polypeptide by

30 coupling via a nucleophilic reactive moiety such as epsilon amino groups of polypeptide lysyl residues. Quantitation of an activated dendrimer intermediate allows control over the composition and purity of the final product.

- 13 -

As an alternative, an NHS ester of a dendrimer carboxyl terminus may be further reacted with 6-bromoacetamido hexylamine ($\text{BrCH}_2\text{CONH(CH}_2)_6\text{NH}_2$; BAHA) to incorporate an electrophilic bromoacetamido group, which 5 forms activated dendrimer termini that may be coupled to sulfhydryl groups of a suitable polypeptide. Other dendrimer terminal functional groups that are suitable as activated termini or for converting to activated termini include maleimidyl, chloroacetyl, hydroxyl, mercapto, 10 carboxyl, allyl, vinyl, halo, oxiranyl, aziridinyl, oxazolinyl, imidazolinyl, isocyanato and isothiocyanato.

Reactive moieties on polypeptides that are suitable for coupling to activated dendrimer termini include, without limitation, sulfhydryl, amino, epoxy, iodoacetyl, 15 aldehyde and phenyl iodoacetamido groups. Reactive moieties may comprise intrinsic functional groups present in the native polypeptide, e.g., epsilon amino groups of lysyl residues or sulfhydryl groups of cysteinyl residues. Illustrative embodiments of intrinsic groups 20 suitable as reactive moieties are sulfhydryl groups of cysteine residues in the hinge region of an Fab' antibody fragment and ϵ -amino groups of lysine residues in calf intestinal alkaline phosphatase.

Reactive moieties also may be introduced onto a 25 polypeptide in a separate reaction. For example, sulfhydryl groups may be introduced by reacting a polypeptide with sulfosuccinimidyl 6-[3-(2-pyridylthio)propionamide] hexanoate (sulfo-LC-SPDP) to introduce disulfide linkages, followed by reduction 30 of disulfide linkages with dithioerythritol (DTE). The average number of reactive moieties introduced per polypeptide may be controlled by appropriate selection of reactant ratios, incubation time, pH, temperature and the like. The actual number of

- 14 -

reactive moieties introduced on a polypeptide may be readily determined by titration methods known in the art.

Compatible activated dendrimer terminal groups and polypeptide reactive moieties preferably are selected to 5 allow activated termini to be coupled to reactive moieties under relatively mild reaction conditions, i.e., physiologically acceptable ranges of temperature (4°- 40°C), pH (6.0-8.5), ionic strength (0.1-0.2 M) and the like. For a polypeptide having one or more sulfhydryl 10 groups as reactive moieties, suitable activated dendrimer termini include electrophilic groups such as epoxy, iodoacetamido or bromoacetamido groups. An appropriate polypeptide reactive moiety to use for coupling to an NHS-activated carboxyl ester dendrimer terminus is an 15 amino group such as the epsilon amino group of a lysine residue in the polypeptide chain. Certain electrophilic groups, such as sulfosuccinimidyl-(4-iodoacetyl) aminobenzoate (sulfoSIAB) are not preferred as activated terminal groups on a dendrimer since it is difficult to 20 functionalize substantially all of the termini under mild reaction conditions with sulfoSIAB.

Certain pairs of groups are not preferred for sequential coupling of polypeptides to dendrimers. For example, the aqueous coupling of dendrimer -COOH terminal 25 groups to -NH₂ groups in a polypeptide is sometimes carried out in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) in neutral or acidic medium. However, the EDC reagent is normally present during the reaction of activated carboxyl termini 30 with a nucleophilic reactive moiety in this method and can produce inter- and intra-molecular linkages between the NH₂ groups of the polypeptide and the COOH groups of both the polypeptide and the dendrimer. The reaction products can also include undesirable cross-linked 35 protein species. Cross-linked protein species often have

- 15 -

less or even no biological activity per mole of protein compared to the biological activity of the native protein.

As described above, a polypeptide in a
5 polypeptide:dendrimer complex exhibits a defined biological activity. The step of coupling a polypeptide to the dendrimer is carried out under conditions that retain such a defined biological activity in the resulting product. However, it is recognized that
10 enhancement, reduction or elimination of other biological activities of the polypeptide may occur. Such enhancement, reduction or elimination is within the scope of the invention, provided that the defined biological activity is retained. In fact, enhancement, reduction or
15 elimination of other biological activities may be desirable in the final polypeptide:dendrimer composition.

The ratio of a first polypeptide to dendrimer produced by a coupling reaction is readily controllable by adjusting the amounts of the two reactants, the number of
20 reactive moieties on the polypeptide, the number of activated termini on the dendrimer and reaction conditions (time, temperature and the like). The reaction product, a first polypeptide:dendrimer complex, typically is purified upon completion of the reaction by
25 gel filtration, e.g., Sephadex®.

The reaction product is effective for coupling a second polypeptide thereto. Effectiveness for coupling of a second polypeptide is readily achieved, by means that depend upon the chemistry of the two couplings. In those
30 situations in which the first and second polypeptides are to be coupled to the dendrimer by similar chemistry (the same or similar reactive moieties on both the first and second polypeptide and the same or similar activated termini on the dendrimer), coupling of the first
35 polypeptide typically will leave a number of activated

- 16 -

terminal dendrimer groups in an activated state, i.e., not all of the activated terminal groups will be involved in coupling to the first polypeptide and will be available for coupling to the second polypeptide. Those dendrimer
5 termini involved in coupling to the first polypeptide are, of course, no longer activated. In this situation, the reaction product of the first coupling is thereafter incubated with a second polypeptide under conditions effective for controllably coupling the second
10 polypeptide to the first polypeptide:dendrimer complex at the desired ratio.

On the other hand, if the chemistry involved in coupling the first polypeptide is different from the chemistry involved in coupling the second polypeptide,
15 the reaction product of the first reaction is thereafter incubated such that at least one dendrimer terminus not involved in coupling to the first polypeptide is activated with a second activation group suitable for coupling a second polypeptide to the dendrimer:first
20 polypeptide complex.

Reaction conditions for coupling a second polypeptide are controlled in a manner similar that described above for the first coupling reaction, such that a desired average number of second polypeptide molecules are
25 coupled to a dendrimer molecule.

The average number of polypeptide molecules per dendrimer will depend to some extent upon the dendrimer generation selected, since higher generation dendrimers support coupling of more polypeptides. Typical
30 polypeptide/ dendrimer ratios are from about 0.1 to about 2 molecules per dendrimer. The end use of a particular polypeptide: dendrimer complex affects the desired ratio in two polypeptide:dendrimer complexes. For example, if a complex comprises a label polypeptide and a specific
35 binding polypeptide and is to be used as an indicator or

- 17 -

specific competitive reagent in a specific binding assay, it may be desirable to have a relatively larger number of label polypeptides per dendrimer compared to the number of specific binding polypeptides per dendrimer.

- 5 Polypeptide:dendrimer complexes may, and often do, have residual dendrimer termini that are not involved in polypeptide coupling. Such termini may have properties that are undesirable in the final product, e.g., may be charged at physiological pH. If desired, such uncoupled
- 10 terminal groups may be converted to or replaced with a more desirable terminal group, e.g., an uncharged group, which conversion or replacement may be termed "blocking". However, it is recognized that blocking is not necessary for many end uses and that the presence of uncoupled
- 15 terminal groups may even be desirable for some end uses.

Polypeptide:dendrimer complexes according to the invention present a number of distinct advantages. First, dendrimers are produced with precise polymer chemistries and can be designed to have a precise number 20 of generations yielding a precise molecular size, weight and surface composition. Because of the uniform and well-characterized chemistry, such parameters remain uniform over different manufacturing lots. The uniformity in dendrimer properties leads to uniformity in 25 polypeptide:dendrimer compositions compared to directly coupled polypeptide-polypeptide conjugates. Second, dendrimers having appropriate interior and surface compositions can be manufactured to be water soluble, such that dendrimer:polypeptide complexes are more likely 30 to remain in solution and maintain solution homogeneity over time. Third, sequential coupling of two different polypeptides to a dendrimer has been discovered to avoid the variations and limitations of simultaneous coupling of polypeptides to a dendrimer.

- 18 -

Polypeptides incorporated into compositions according to the invention surprisingly retain the defined biological activity present in the unincorporated native polypeptide. Compositions having a second polypeptide 5 exhibit the defined biological activity of both the first and the second polypeptides, regardless of the similarity or dissimilarity between the two coupling chemistries. Although the present invention is not bound by theory, it is believed that factors such as steric inhibition and 10 undesired coupling to active site polypeptide residues do not occur, contrary to expectations.

Sequential coupling of polypeptides to a dendrimer allows control over the complex formed regardless of the relative reactivities of the polypeptides, even when the 15 same chemistry is utilized for both coupling reactions. In contrast, successful simultaneous coupling requires the first and second polypeptides to have the same or similar reactivities with the dendrimer/activated dendrimer; if the first and second polypeptides have 20 different reactivities, the more reactive polypeptide will preferentially react with the dendrimer. For example, it was found that all efforts to simultaneously couple alkaline phosphatase (ALP) and an antibody to a dendrimer gave a product in which only ALP was coupled to 25 the dendrimer. Thus, simultaneous coupling of two polypeptide species requires two very similar reactivities which is very difficult to achieve. Alternatively, the reactivity of one of the two 30 polypeptide species can be modified prior to simultaneous coupling which, however, can cause a loss in biological activity.

Dendrimer:two-polypeptide compositions are useful as industrial bioreactors, as biological standards, or as affinity chromatography media. Many biological systems 35 and enzyme reactors depend on sequential reactions

- 19 -

catalyzed by different enzymes. In these reactions, the product of one enzyme-catalyzed reaction is the substrate for the other enzyme. These coupled reactions have found broad applications in a number of processes, including
5 commercial chemical production as well as analytical purposes. A few examples are: the conversion of sucrose to fructose by a combination of invertase-glucose isomerase, conversion of D-amino acids to α -keto acids by a combination of D-amino acid oxidase-catalase,
10 quantitation of tryptophan by a combination of tryptophanase-lactate dehydrogenase and microassay of L-aspartate by the combination of aspartate aminotransferase-malate dehydrogenase. Dendrimer:two-polypeptide complexes are especially suited for these
15 kinds of applications either in homogeneous solution or separated from the reaction mixture in a hollow fiber reactor or immobilized on a solid surface.

Dendrimer:two-polypeptide compositions are useful in chromatographic procedures requiring purification of two
20 or more chemical species by differences in their properties. Thus, a separation of two species, either from each other or from a complex mixture, can be carried out by attachment of first and second antibodies to a dendrimer, each antibody having a different pH
25 dissociation curve. In this procedure the first species can be dissociated from its antigen-antibody complex at a first pH, e.g. 6.0, whereas the second species can be dissociated at a second pH. Alternatively, this process can be carried out by addition of dendrimer:two-
30 polypeptide complex to a mixture of the two species followed by separation of a first antigen-antibody complex by ultrafiltration. Alternatively, the dendrimer:two-polypeptide complex can be separated from a mixed solution by using an appropriate size membrane.

- 20 -

A preferred use for a polypeptide:dendrimer complex is as an indicator in a specific binding assay, i.e., assays that utilize specific receptors to distinguish and quantify analytes. In such assays, an analyte must be
5 distinguished from other components found in a sample, which is accomplished by reacting the analyte with an indicator containing a specific receptor for that analyte and a label. The amount of indicator present is determined by detecting the amount of label present and
10 correlating this amount to the concentration of analyte. The term "indicator" in the context of this invention comprises a dendrimer coupled to a specific receptor polypeptide and a label polypeptide.

A polypeptide receptor, e.g., an antibody, antibody
15 fragment, or other specific binding protein (such as Intrinsic Factor or Folate Binding Protein), of an indicator is characterized by having a reversible specific binding affinity for an analyte or an analogue of that analyte. As used herein, an analogue generally
20 is an analyte derivative carrying a marker suitable for direct or indirect detection. The analogue is capable of binding to a receptor with about the same specificity and affinity as the analyte.

A label of an indicator comprises a polypeptide
25 suitable for direct or indirect detection of the amount of indicator present, preferably in a quantitative manner. A label may be, for example, an enzyme producing a fluorescent, colorimetric, chemiluminescent, phosphorescent, radiometric or hybridized product after
30 contact with a substrate. Illustrative examples of enzymatic labels include alkaline phosphatase, β -galactosidase, glucose oxidase, peroxidase (such as horseradish peroxidase), urease, catalase, adenosine deaminase, glycosidase, protease, esterase, DNase, RNase
35 and acetylcholinesterase.

- 21 -

Dendrimer:two-polypeptide complexes are useful as indicators in immunoassays such as those using glass fiber filters as a solid phase. Giegel et al., Clin. Chem. 28:1894-98 (1982) and in U.S. Patent No. 4,517,288, 5 incorporated by reference herein. It is desirable to minimize non-specific binding of indicators onto a solid phase such as glass fiber. Dendrimer:two-polypeptide indicators of the invention advantageously have very low levels of non-specific binding.

10 The dendrimer-polypeptide complexes of the present invention are applicable to a variety of specific binding assay formats. For example, various direct-binding assays may be employed with these reagents. In such assays, receptors such as antibodies or binding proteins 15 are immobilized on a solid phase. The immobilized receptor complexes are contacted with a sample containing the analyte of interest. Following binding of the analyte by the immobilized receptor, the solid phase is washed and then contacted with a dendrimer:two- 20 polypeptide indicator, one of the polypeptides having affinity for the analyte and the other polypeptide functioning as a label. The extent to which the indicator is present on the solid support can be correlated with the amount of unknown analyte as 25 disclosed, for example, in Tijssen, P., Laboratory Techniques in Biochemistry and Molecular Biology, Practice and Theory of Enzyme Immunoassay, pp. 173-219 (Chapter 10) and pp. 329-384 (Chapter 14), Elsevier Science Publishers, Amsterdam, The Netherlands, 1985.

30 Dendrimer:two-polypeptide complexes also may be used as specific competitive reagents in competitive assay formats. In such formats the solid phase, containing immobilized receptor or other molecule with specificity for a selected analyte, is contacted with a sample 35 presumably containing such an analyte and with a specific

- 22 -

competitive reagent. The specific competitive reagent comprises a dendrimer coupled to a polypeptide analogue of the analyte and a polypeptide functioning as a label. In this embodiment, the analogue competes with the sample 5 analyte for binding to the receptor immobilized on the solid phase.

In an alternative embodiment, analyte may be coupled to a solid phase and contacted with a sample and with a specific competitive reagent, comprising a dendrimer 10 coupled to a polypeptide functioning as a specific receptor for the analyte and to a polypeptide functioning as a label. In this format, sample analyte competes with solid phase analyte for binding of the soluble receptor. In both embodiments, the amount of polypeptide label 15 bound to the solid phase after washing provides an indication of the levels of analyte in the sample. That is, the amount of label bound to the solid phase is inversely proportional to the amount of analyte in the sample.

20 Radial partition immunoassay as disclosed in Giegel et al., Clin. Chem. 28:1894-98 (1982) and in U.S. Patent No. 4,517,288, incorporated herein by reference, is an assay procedure in which all steps are conducted directly on a solid phase. Antibodies or other receptor reagents are 25 immobilized on a small area of glass fiber filter paper. Various calibrators containing known amounts of an analyte to be detected or various unknown samples potentially containing such an analyte are then incubated with this immobilized receptor. Following appropriate 30 additions of indicators or other labeling reagents, excess reagents are removed from the center area of the filter paper by application of a wash fluid. In the case of an enzyme immunoassay, the wash fluid may contain the substrate for the enzyme, thus initiating the enzyme 35 reaction simultaneously with the wash step. Preferably

- 23 -

the action of the enzyme on the substrate generates a fluorescent signal. The enzyme activity in a part of the center area is then quantifiable by front-surface fluorometry. Depending on the assay format, i.e., direct
5 binding assay or competitive assay, the rate of fluorescence is directly or inversely proportional to the concentration of analyte in the sample. Dendrimer:two-polypeptide complexes may be used as indicators in radial partition immunoassays.

10 Alternatively, dendrimer:two-polypeptide compositions disclosed herein may be used as indicators in "pre-mix" specific binding assays as disclosed in U.S. Patent Application Serial No. 08/227,364, incorporated herein by reference.

15 Various instruments are available for applying dendrimer:two-polypeptide indicators or specific competitive reagents, as well as various other binding assay reagents to a solid phase, washing the solid phase, and reading the amount of indicator or competitive
20 reagent bound to the solid phase. In a preferred embodiment, the solid phase comprises glass fiber filter tabs and the instrument comprises a Stratus® or Stratus® II Immunoassay System, available from Dade Diagnostics Inc. This instrument is a batch-processing bench-top
25 instrument, adapted to process tabs in the radial partition immunoassay format. Giegel et al., Clin. Chem. 28:1894-98 (1982). The instrument includes fluid dispensers for sample, conjugate and substrate washes. Microprocessor-controlled stepping motors aspirate and
30 dispense required aliquots of reagents. All timing and operational aspects of the dispensers are predetermined by a program routine within the analyzer. The instrument also includes a tab transport system, heated platens with temperature monitoring, sample and reagent fluid pumps, a
35 read station, data processing, and means for tab

- 24 -

disposal. For quality control, the instrument microprocessor control program periodically verifies critical operating conditions such as reference voltages, temperatures, and dispensing settings, and flags for out-
5 of-limit values.

The polypeptide-dendrimer complexes of the invention can be used in analytical protocols for a variety of biological materials. For example, dendrimer:polypeptide complexes may be useful for immunoassay of blood or urine
10 for the presence of therapeutic drugs, natural or synthetic steroids, hormones, enzymes or antibodies.

Other analytes that can be quantitated in such protocols include, without limitation, digoxin, dilantin, phenobarbital, theophylline, gentamicin, quinidine, and
15 the like. Dendrimer-polypeptide complexes prepared in the foregoing manner can also be used as indicators or specific competitive reagents for the detection of steroids such as cortisol, aldosterone, testosterone, progesterone, and estriol or serum protein such as
20 ferritin. Hormone levels are also capable of determination through the use of dendrimer-polypeptide indicators or specific competitive reagents of the present invention. These hormones include, without limitation, thyroid hormones such as tetraiodo-and
25 triodo-thyronine and thyroid stimulating hormone (TSH); peptide hormones such as insulin, corticotropin, gastrin, angiotensin, and proangiotensin; and polypeptide hormones such as thyrotropin, levetotropin, somatotropin and human chorionic gonadotropic hormone (HCG).

30 Other applications of the complexes of the present invention include assay of relatively small molecules involved in metabolism, e.g., folate, to assay polypeptide antigens and antibodies associated with infectious disease, e.g., antigens and antibodies
35 associated with HIV, hepatitis, CMV, syphilis, Lyme

- 25 -

disease agents, and numerous other infectious agents. Other applications include assay of compounds associated with cardiac testing, e.g., creatine kinase isozyme MB (CKMB), troponin, myoglobin, carbonic anhydrase 3 and 5 digoxin and compounds associated with cancer diagnosis, e.g., carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP) and human chorionic gonadotropin hormone (HCG).

Polypeptide-dendrimer compositions according to the invention are less expensively and more rapidly prepared 10 than directly coupled protein-protein conjugates, or simultaneously coupled two polypeptide:dendrimer complexes, since there is less need for extensive quality control and standardization procedures. The ratio of first polypeptide:dendrimer in compositions according to 15 the invention may be readily controlled, as can the ratio of second polypeptide:dendrimer in compositions containing a second polypeptide.

Other advantages include the fact that less protein is required to achieve a given sensitivity of an indicator, 20 compared to directly coupled polypeptide-polypeptide conjugates. In some cases, 25% less polypeptide is required. The higher specific biological activity is at least partially a result of the controllable, sequential coupling that is achieved by the present invention.

25 Another advantage is that indicators and specific competitive reagents of the present invention may be used to achieve signal amplification not achievable with directly coupled polypeptide-polypeptide conjugates or simultaneously coupled polypeptide:dendrimer complexes.

30 This is done by controllably coupling a relatively larger number of polypeptide label molecules per dendrimer and a relatively smaller number of specific binding polypeptide molecules per dendrimer. Such controlled coupling and signal amplification is difficult to achieve with other 35 polypeptide-polypeptide indicators.

- 26 -

The invention will be further understood with reference to the following illustrative embodiments, which are purely exemplary, and should not be taken as limiting the true scope of the present invention as described in the 5 claims.

EXAMPLE 1

Phenyl iodoacetamido- and sulfhydryl-activated dendrimers.

Experiments were carried out to activate 10 ethylenediamine dendrimers from generations 1 through 5 (E1-E5) by incorporating phenyl iodoacetamido groups onto amino terminal groups of the dendrimer. A limited number of phenyl iodoacetamido groups were incorporated by adding one-fifth volume of 0.5 M sodium phosphate buffer, 15 pH 7.0 to an aqueous solution containing approximately 2% dendrimer by weight (Michigan Molecular Institute, Midland, Michigan). The pH of the solution was adjusted to 7.6. A freshly prepared solution of 20 mg/ml sulfo-SIAB (Pierce Chemical) was added with constant mixing to 20 the dendrimer solution at about a 10: to 25:1 molar ratio (sulfo-SIAB:dendrimer). The mixture was incubated at 30°C for one hour and then loaded onto a Sephadex® G-25 column prepared and eluted with 0.1 M sodium acetate, pH 4.5. The first peak eluted from the column, as detected 25 by absorption at 280 nm, contained the derivatized dendrimers. It was collected and either stored in an ice bath for no more than 12 hours prior to its use or stored frozen at -10°C for up to two weeks. To incorporate the maximum possible number of phenyl iodoacetamido groups, a 30 2.5% methanolic solution of E2 (23.4 mM) was mixed slowly with a solution of SIAB in THF-methanol (234 mM; Pierce Chemical Co.). After ten minutes at ambient temperature, a white solid precipitated out from an initially clear solution. Once isolated, this precipitate was found to

- 27 -

be insoluble in all common solvents, such as alcohol, dimethylsulfoxide (DMSO) or dimethylformamide (DMF) and buffers of pH 2.0 to 11.0. A suspension of material showed a positive color reaction for amino groups as

5 tested with TNBS at room temperature by a procedure similar to that described by L.U. Obi 'Application of the 2,4,6-trinitrobenzene-1-sulfonic acid (TNBS) method for determination of available lysine in maize seed' Agric. Biol. Chem.: 46, pp 15-20 (1982).

10 Fifth-generation dendrimer, E5, was reacted with Sulfo-LC-SPDP (Sulfosuccinimidyl 6-[3-[2-pyridyldithio] propionamide]hexanoate), from Pierce Chemical Company, Rockford, Illinois in aqueous methanol at ambient temperature for 1 hour. A 8:1 molar ratio of the

15 activated reagent:dendrimer was used for this reaction. About 4.0 protected sulfhydryls/dendrimer were incorporated at terminal groups to form protected E5-SH. The product (E5-S-S-Py) was reacted with gluconolactone, butyrolactone or acetoxyacetyl chloride in an attempt to

20 convert the remaining amino groups in E5-S-S-Py to hydroxyl groups. Analysis of the reaction products indicated that complete conversion of the remaining amino groups to hydroxyl groups in SPDP-treated E5 was not attained with such reagents.

25 SPDP-treated E5 was carboxylated with succinic anhydride to form succinylated-E5-S-S-Py. The reactions were carried out by treating the methanolic solution of E5-S-S-Py with an excess of succinic anhydride solution in THF at ambient temperature. Completion of the

30 reaction was monitored by the absence of a color reaction with TNBS which detects the presence of free primary amino groups. Analysis of the reaction product indicated that remaining amino groups in E5-S-S-Py were essentially replaced by a carboxyl group. The protected moieties on

35 the sulfhydryl groups of succinylated-E5-S-S-Py were then

- 28 -

removed using dithioerythritol (DTE). The resulting product, succinylated-E5-SH was found to form an insoluble precipitate on storage at -20°C.

Example 2.

5 Linking of Reactive Moiety to Polypeptides

An antibody directed against creatine kinase isozyme MB (CKMB, Conan, ATCC Accession No. HB8939, molecular weight about 150,000) was purified over an Affi-Prep Protein A column (BioRad) by eluting the adsorbed protein using 100
10 mM phosphate, pH 6.0, containing 5 mM EDTA.

The anti-CKMB antibody was digested at 37°C with 2% pepsin for 24 hours at pH 4.2 to produce the fragment F(ab')₂ with a molecular weight of 100,000. The anti-CKMB F(ab')₂ at 3.2 mg/ml in 100 mM phosphate, pH7.0 was
15 mixed with sulfoSIAB (in water) at a 25-fold molar excess of sulfoSIAB and incubated at 30°C for 1 hour. The resulting SIAB-activated F(ab')₂ was purified by gel filtration on Sephadex® G-25 and was determined to contain 0.6 reactive phenyl iodoacetamido
20 moieties/polypeptide.

Calf intestinal alkaline phosphatase (referred to herein as ALP) was reacted at 2.6 mg/mL in 100 mM phosphate buffer, pH 7.6 at a 20-fold molar excess of Sulfo-SIAB in essentially the same manner as described
25 above for F(ab')₂. After purification, sulfoSIAB-activated ALP was found to contain 4.6 reactive phenyl iodoacetamido moieties/polypeptide.

Example 3.

Sequential Coupling of SIAB-polypeptides to SH-dendrimers
30 Succinylated-E5-SH from Example 1 was reacted with SIAB-activated F(ab')₂ from Example 2 at pH 6.0, 4° C for 20 hours in 100 mM phosphate buffer containing 5 mM EDTA buffer. The product was purified by gel filtration on

- 29 -

Sephadex G-25. Purified F(ab')₂-succE5-SH was reacted with the SIAB-activated ALP of Example 2 at pH 7.60, 4° C for 94 hours. The resulting product was purified by gel filtration on AcA-34, yielding ALP-succE5-F(ab')₂. The 5 molecular weight of the product was calculated to be 706,860. The molecular weight of the product is more than twice that of an ALP-Fab' indicator prepared by direct conjugation using SIAB (ALP-SIAB-Fab').

The ALP-succE5-F(ab')₂ product was used as an indicator 10 in a CKMB assay as described in U.S. Patent application Serial No. 08/021,928, incorporated by reference herein.

The assay was performed on a Stratus® II instrument by aspirating and delivering about 60 μl of a selected calibrator onto a glass fiber tab. About 20 μl of ALP- 15 succE5-F(ab')₂ (167 ng protein/ml) were then delivered to each tab. The instrument then aspirated about 70 μl of substrate wash (pH 9.0 Diethanolamine buffer containing 1.0 mM 4-methylumbelliferyl phosphate (MUP), alkaline phosphatase inhibitor, stabilizers, blue dye, surfactant 20 and 0.1% sodium azide) and released 20 μl and 50 μl sequentially to each tab. As soon as the second substrate wash was delivered, the initial fluorescence rates were measured and recorded in instrument memory.

The amount of fluorescence generated by action of ALP 25 on the MUP substrate was detected by the instrument and converted to a "rate" expressed in voltage per unit time, which is presented in the Tables and Figures as mV/min. The rate is a measure of the intensity of the fluorescence, which is, in turn, a measure of the amount 30 of polypeptide:dendrimer complex bound to the reactive portion of the tab.

If an unknown sample is being measured during an instrument run, the fluorescence rates of individual calibrators are measured and the values directed to 35 storage locations in a microprocessor memory. After all

- 30 -

calibrators have been measured, the program calculates "Rodbard" parameters A, B, C and D using a multi-pass linear regression routine that fits a mathematical relationship to the measured data points in the form
 5 shown in the following equation:

$$R = \{(A-D/[1+B(X/C)]+D\}$$

where R is the fluorescence rate and X is the corresponding concentration. The equation is a generalized sigmoidal curve that has been reported to
 10 give an excellent fit in various immunoassay systems. Based on the resulting A, B, C and D parameters stored in memory, the instrument provides a concentration readout for the samples assayed.

For this experiment, calibrators A, B and F were
 15 prepared in a Tris-buffered solution (pH 7.5) including BSA, stabilizer and 0.1% sodium azide as a preservative. Calibrator solutions A, B and F contained concentrations of 0.0, 3.9 and 131.6 ng of CKMB/ml, respectively.

The results of the experiment are shown in Table 1.
 20 Similar results were obtained in two additional experiments.

Table 1.

Fluorescence Response of ALP-SuccE5-F(ab')₂

Calibrator	A	B	F
25 Response (MV/min) ^a	698	872	3898

^a 500 ng of polypeptide/ml of indicator solution.

EXAMPLE 4

Epoxide- and SIAB-Dendrimers

30 A carboxymethylated-E5 dendrimer (CME5) was prepared by treatment of E5 with an 108 fold excess of bromoacetic acid in methanol solution at 37°C. Partially (77%) hydroxylated-E5 (77%E5) was made by using an ethylenediamine/ethanolamine mixture in the final

- 31 -

reaction step to form the fifth generation termini.

(Michigan Molecular Institute, Midland, MI).

Dendrimers E5, E2, 77%E5 and succinylated-E5 were reacted with epibromohydrin in the presence of a base such as triethylamine or suspended solid sodium carbonate for 16 hours at ambient temperature in 50% ethanol. The dendrimer reaction products contained termini with epoxide groups derived from the epibromohydrin reactant. Epoxide-activated dendrimer derivatives were completely soluble in 50% alcohol.

The number of epoxy groups incorporated into the dendrimer reaction products was quantitated by a titration procedure similar to that described in Ngo, T., ed., Nonisotopic Immunossay, Plenum Press, New York (1988), p. 37. The titration was performed by incubating a known volume (0.9 mL) of the activated-dendrimer solution with 0.1 mL of 0.5 mM DTE at pH 6.0 for 2.5 hours at 37°C. The amount of excess DTE that remained in the reaction mixture was quantitated by addition of 40 µL of a 5mM aqueous alcoholic solution of dithiodipyridine (Aldrich Chemical Co.) and measuring absorption at 324 nm. The amount of DTE consumed during this reaction is equivalent to the concentration of the active groups present on the activated-dendrimer. The titration results indicated that 95-99% of the terminal amino groups on each dendrimer had been linked to an epoxy reactive group after treatment with epibromohydrin.

Carboxymethylated-E5 and 77% hydroxylated-E5 were each treated at pH 7.4 with sulfoSIAB at molar ratios of 12:1 and 8:1, respectively, of dendrimer:sulfoSIAB. These challenge ratios allowed the retention of a small number of free amino groups on each dendrimer derivative.

- 32 -

Example 5

Sequential Coupling of SH- and CHO-Polypeptides
to Epoxy- and SIAB-Dendrimers

An Fab' fragment of anti-CKMB antibody (molecular weight about 46,000, herein termed Fab') was prepared by DTE treatment of F(ab')₂ (Example 2) at pH 6.0 for 1 hour at 37°C in 100 mM phosphate buffer. The sulfhydryl moiety in the hinge region of the Fab' was utilized as a reactive moiety to couple the polypeptide to dendrimers.

ALP was treated with sodium periodate to introduce reactive aldehyde moieties on the carbohydrate groups of ALP to form ALP-CHO. This reaction was carried out by a procedure similar to that described in Bioconj. Chem.:5, pp. 482-490 (1994).

ALP also was treated with Sulfo-LC-SPDP by a procedure identical to that described for activation of ALP by sulfo-SIAB (Example 2); the reaction product then was reduced at ambient temperature by adding 1 part 100 mM DTE, pH 7.6, to 9 parts reaction product and incubating for 30 minutes. The resulting polypeptide product (ALP-SH) contained about 4.5 sulfhydryl reactive moieties linked to reactive amino groups of lysyl residues in ALP.

Three separate reactions then were carried out in which Fab' and the ALP derivatives were sequentially coupled to derivatives of E5. In reaction 1, Fab' was reacted with epoxy-activated E5 (Example 4) by concentrating a reaction mixture, containing 12 mg Fab' and 10 mg activated-E5 in 100 mM phosphate, pH 6.5, such that the protein concentration in the incubation mixture was at about 5.0 mg/mL. After incubation at 4°C for 23 hours, the pH of the reaction mixture was adjusted to 7.67 and incubation continued for an additional 17 hours at 4°C. The resulting first polypeptide:dendrimer complex was purified by gel filtration over a AcA-44 column and found to contain about 3.1 uncoupled epoxide-activated termini.

- 33 -

Purified Fab'-E5-epoxide (3.9 mg) then was added to a solution of ALP-SH (3.0 mg). The reaction mixture, in 100 mM phosphate, pH 7.6, was concentrated to a total protein concentration of about 5.0 mg/mL and then

5 incubated at 4°C for 63 hours. Excess free sulfhydryls were quenched by the addition of 10 μ L N-ethylmaleimide (10 mg/mL in DMF) for each mL of the reaction mixture.

In reaction 2, Fab' (3.2 mg) was reacted with SIAB-activated carboxymethylated-E5 (termed CME5-SIAB, 14 mg;

10 Example 4) in 100mM phosphate, pH 6.0. After incubation at 4° C for 24 hours, the resulting first polypeptide-dendrimer complex was purified by gel filtration over a Sephadex® G-25 column and found to contain about 16 unconjugated SIAB-activated termini. Purified Fab'-E5

15 (CH₂COOH)-NHCOPhNHCOCH₂I complex (2.2 mg) was then added to a solution of ALP-SH (3.1 mg) and incubation carried out at pH 7.6 as described above in reaction 1.

In reaction 3, the order of coupling of the two polypeptides to dendrimer was reversed. ALP-CHO was
20 coupled by concentration of a solution containing 8.1 mg ALP-CHO and 15.9 mg SIAB-activated CME5 in 100 mM phosphate, pH 7.6. The reaction mixture (1.2 mL, containing about 5.0 mg/mL protein) was incubated at 4°C for 16 hours. The pH was adjusted to pH 6.30 and the
25 mixture combined with 200 μ L of sodium cyanoborohydride (30 mg/mL in water). After one hour at ambient temperature, the reaction mixture containing ALP:dendrimer complex was purified by gel filtration over Sephadex G-25 in 100 mM phosphate, pH 7.6. Purified ALP-
30 E5(CH₂COOH)-NHCOPhNHCOCH₂I complex (4.7 mg) was then added to a solution of Fab' (2.3 mg) and incubated for 24 hours as described above in reaction 1.

The three dendrimer:polypeptide reaction products were each passed over an Aca-34 column and the A₂₈₀ of
35 pertinent fractions was measured. The column profiles

- 34 -

showed the presence of species with molecular weights of about 300,000, demonstrating that an ALP-E5-Fab' complex was formed in all three reactions.

The product of reaction 1 was used as an indicator in a 5 Stratus® CKMB assay as described in Example 3. The product had fluorescence rates of 4364 and 4899 mV/min for calibrators A and F, respectively. Similar results were obtained for the products of the other two reactions.

10

EXAMPLE 6

Coupling of ALP to SIAB-, Epoxy-
and Iodoacetyl-Dendrimers

ALP-77%E5-NHCOPhNHCOC₂I, containing about 15.3 SIAB-activated uncoupled termini, was prepared by coupling 15 ALP-CHO with SIAB-activated 77% E5 using the conditions described for Reaction 3 (Example 5) and purified by gel filtration over Sephadex® G-25. About 20 µl of the product was used as an indicator (at 0.94 ng protein/ml indicator) in a Stratus® CKMB assay as described in 20 Example 3. The fluorescence response was 2028 mV/min on a paper tab containing no calibrator or sample (blank paper tab).

Dendrimer E2 was activated with epibromohydrin as described in Example 4. E2 also was activated with N-25 hydroxysuccinimidyl iodoacetate (NIA) (BioAffinity Systems, Roscoe, Illinois). A solution of NIA in alcohol-THF(1:1) was added slowly to a 50% alcoholic solution of E2, containing 1% w/v E2 dendrimer and incubated at ambient temperature for 1 hour. In this 30 reaction, the dendrimer was activated with a twenty fold molar excess of NIA. The resulting iodoacetyl-activated dendrimer was obtained as a yellow resin on evaporation of the solution under reduced pressure. The product was dissolved in a 1:1 mixture of alcohol and 100 mM

- 35 -

phosphate, pH 7.2 and used immediately. Essentially all dendrimer termini were activated in these procedures. The two activated E2 derivatives, containing electrophilic epoxy or iodoacetamido termini, were each 5 coupled to ALP-SH (containing 2.6 free sulfhydryls per polypeptide molecule) as described in Example 5.

Each ALP-dendrimer complex was used as an indicator in a Stratus® CKMB assay on a blank paper tab as described above. The fluorescence response using ALP-E2-COCH₂I was 10 about 1058 mV/min at 100 ng protein/ml indicator. The fluorescence response of ALP-E2-epoxide was calculated to be about 50,130 mV/min at 100 ng protein/ml indicator.

The ALP-E2-COCH₂I complex was incubated with 1/5 volume of 100mM aminoethanethiol in 100mM phosphate buffer, pH 15 7.2 for 16 hours. Aminoethanethiol reacts with the reactive iodoacetyls present in the dendrimer-polypeptide complex and introduces an amino group in place of each iodoacetyl. The aminoethanethiol-treated complex was then used as an indicator in a Stratus® CKMB assay with 20 blank paper tabs as described above. The fluorescence response using the aminoethanethiol-treated complex as indicator was about four-fold higher than the response using untreated complex.

EXAMPLE 7

25 Coupling of ALP-SH to Iodoacetyl-Dendrimers

Sulfhydryl reactive moieties were linked to ALP as described in Example 5, except that a 10-fold excess of Sulfo-LC-SPDP at pH 7.0 was used. The ALP-SH product contained one free sulfhydryl per mole of protein.

30 NIA was used to activate the amino termini of various E1-E5 dendrimers with iodoacetyl groups. To a 50% alcoholic solution of dendrimer (1-3%, w/v) a THF solution of NIA, containing 10-25% excess of the activating reagent, was added dropwise. Thus, for

- 36 -

example, E1 and E3 containing 8 and 32 terminal groups, respectively, were reacted with 10:1 and 35:1 molar ratios of NIA:dendrimer. After reaction for one hour at ambient temperature, most of the volatile reagents were 5 removed on a rotary evaporator at a bath temperature of <25°C. The residual aqueous solution/suspension was diluted with an equal volume of alcohol. The aqueous alcoholic, slightly turbid, solution of NIA-activated dendrimer was stored at 4°C until used, normally within 4 10 hours of preparation.

Fluorescamine titration (Lai, C.Y., Methods Enzymol. 47:236-243, 1977) of NIA-activated dendrimers indicated that none of the primary amino groups originally present could be detected. This observation suggested that >99% 15 of all the primary amino termini had been converted to NHS-activated termini by this reaction. The number of NIA-activated termini in E1 (IAE1) was not determined due to the lability of the group.

ALP-SH was coupled to NIA-activated E1 by incubating 20 1.0 ± 0.1 mg/ml of the ALP-SH product described above (12.0 ml, 85 µM; 100 mM phosphate, pH 7.0) with about 0.1 volume of 50% alcoholic solution of IAE1 (1.5 ml; 20 mM). The mixture was stirred gently at 4°C for 16 hours. The reaction product, ALP-SCH₂COHN-E1-NHCOCH₂I, was purified 25 by gel filtration on an AcA-44 column and shown by DTE titration to contain about 1.3 moles of iodoacetyl per mole of protein. When the reaction product (referred to as ALP-E1) was used as an indicator (500 ng protein per mL indicator) on a blank paper tab in a CKMB assay, a 30 fluorescence rate of 146 mV/min was observed. A fluorescence rate of 9713 mV/min was observed under the same conditions using an ALP-SCH₂COHN-E2-NHCOCH₂I preparation in which the ALP-SH polypeptide contained about 2.6 sulfhydryls per ALP molecule. Unless otherwise 35 indicated, experiments in Examples 8-11 used an ALP

- 37 -

preparation containing an average of one sulfhydryl group per polypeptide molecule.

Similar experiments then were carried out with other dendrimers having iodoacetyl-activated amino termini.

5 The fluorescence response results on blank tabs for a number of iodoacetyl-activated dendrimer:ALP complexes are shown in the Table 2.

Table 2.
Properties of ALP-Dendrimer Complexes

10	Complex ^e	Fluorescence ^a	Reactive Iodoacetyl Groups ^d
		100 ^c 500 ^c	
	ALP-E1	35 146	1.3
	ALP-E2	31 265	2.5
	ALP-E3	169, 205 ^b	5.8, 6.8
15	ALP-E4	242, 185	8.9, 11.7
	ALP-E5	554	13.7
	ALP-77%E5	1206	15.2
	ALP-CME5	1798	6.7

^a Rates in mV/min using each complex as an indicator in a Stratus® II instrument.

^b Duplicate numbers indicate results from two separate experiments.

^c Concentration of indicator used in ng polypeptide/ml solution.

^d Number of reactive groups determined by titration of reactive groups using DTE as described in Example 4.

25 ^e ALP reactant contained one sulfhydryl group per polypeptide molecule.

The number of iodoacetyl groups present in the ALP:dendrimer complexes is generally lower than expected, based on the number of the amino groups present in each 30 of the dendrimers. It is possible that non-activated, uncoupled amino group termini of a dendrimer may have reacted with neighboring iodoacetyl groups to form non-reactive cyclic structures. Although such a reaction is expected to be relatively slow, amino group termini in 35 dendrimers may be more reactive. In addition, iodoacetyl groups incorporated into dendrimers may be more reactive than iodoacetyl groups incorporated into other types of molecules.

- 38 -

The specific enzyme activity was tested for the above dendrimer-polypeptide complexes using para-nitrophenol phosphate. The activity, expressed as units/mg protein, was found to be almost identical for all of the tested 5 derivatives. This result indicates that the dendrimer generation to which ALP was coupled did not have a detrimental effect upon the enzymatic activity of ALP.

EXAMPLE 8

Coupling of Fab' to ALP-Iodoacetyl-Dendrimers

10 Fab' was coupled to each of the ALP:dendrimer complexes of Example 7 by incubating a reaction mixture containing about 5 mg/mL total protein in 100 mM phosphate-1.0 mM MgCl₂, pH 7.6. This mixture contained 1.5 to 1.9 mg of Fab' for each mg of the ALP:dendrimer complex. This 15 ratio represents a >5-fold molar excess of Fab over the amount of ALP:dendrimer complex. After incubation at 4°C for 24-60 hours any free sulfhydryls were quenched by the addition of N-Ethylmaleimide (NEM) as described in Example 5. After purifying the products as described in 20 Example 9, the dendrimer:two polypeptide complexes were used as indicators in a CKMB assay as described in Example 3. The results are shown in Table 3.

- 39 -

Table 3.
Fluorescence Response of ALP-E_x-Fab' Complexes

Indicator	Fluorescence Response(mV/min)			Protein Conc.(ng/ml)
	A	B	F	
CXMB-133 ^b	107	317	7972	
ALP-E1-Fab'	124	329	7764	532
ALP-E2-Fab'	132	393	7910	618
CXMB-136	99	409	8910	597
ALP-E3-Fab'	86	358	8314	444
ALP-E4-Fab'	187	486	9479	578
ALP-E5-Fab'	202	410	6721	9260

^a Calibrators A, B and F contained 0.0, 3.9 and 131.6 ng of CKMB/mL, respectively.

^b CXMB-133 and CXMB-136 are indicators used in Stratus® II CKMB assay kits, comprising ALP directly coupled via SIAB to Fab'.

The results show that the fluorescence rates using an indicator composition comprising two polypeptides sequentially coupled to a dendrimer are similar to the rates for directly coupled ALP-Fab' conjugates currently used as indicators in a specific binding assay. The results further indicate that ethylenediamine core dendrimers, between generations 1 to 5, can be effectively used to sequentially couple two different proteins and form two polypeptide:dendrimer complexes in which the native biological activity of each polypeptide remains substantially the same as the activity of unconjugated polypeptide.

EXAMPLE 9

30 Column Profiles of Polypeptide-Dendrimer Complexes

The ALP-E_x-Fab' derivatives described in Example 8 were passed over an AcA-34 column (1.6 cm by 100 cm diameter) using a buffer containing 10mM Tris, 100 mM NaCl, 1.0 mM MgCl₂, 0.1 mM ZnSO₄ and 0.1% sodium azide, pH 7.00.

35 Higher molecular weight species elute in the earlier fractions under these conditions. Fractions (2 ml) were collected and the absorbance at 280 nanometers (A₂₈₀) was

- 40 -

measured for each fraction. Figures 1 to 5 show the column profiles of the complexes formed using first to fifth generation ethylenediamine dendrimers, respectively. Arrows in each figure indicate fractions 5 of the eluted material that were pooled for testing in a Stratus assay as described in Example 8.

Polypeptide-dendrimer complexes using first or second generation dendrimers appeared to be more homogeneous than the other dendrimer complexes (Figures 1 and 2).

10 The column profile of ALP-E3-FAB' (Figure 3) was almost identical to that of an ALP-Fab' complex directly conjugated by SIAB chemistry (not shown). In both cases, a high molecular weight shoulder at about fraction 32 precedes the main conjugate peak at about fraction 43.

15 E4 and E5 polypeptide-dendrimer complexes produced higher molecular weight species than did E1-E3 complexes. At essentially the same protein concentration, fractions of the first peak in the ALP-E4-FAB' profile (fractions 23 to 29, Figure 4) showed about half the activity in a

20 Stratus® CKMB assay compared to the fractions of the main peak (fractions 33 to 40, Figure 4). The results in Table 3 represent activity of the pool from the main peak fraction. The ALP-E5-Fab' complex used in Table 3 was collected from fractions 20 to 28 (Figure 5); this

25 complex required a much larger amount of protein in order to give fluorescence response readings in a Stratus® assay compared to the amount of protein required by the other complexes (Table 3).

ALP-E3-Fab' complex was also purified by hydrophobic 30 interaction chromatography on an Octyl-Sepharose column (0.8 x 6 cm). In hydrophobic interaction chromatography, the more hydrophobic polypeptide/dendrimer species in the reaction product are eluted in n-propanol/triethanolamine buffer. The effective protein concentration of the 35 fractions from this column are shown in Table 4.

- 41 -

Table 4.
Effective Protein Concentration^c
of Octyl-Sepharose Column Fractions
Column Fraction

5	Complex	TEA	TEA-10% PROPANOL
	ALP-SIAB-Fab' ^a	319 ^b	158
	ALP-E3-Fab'	560	386

^a ALP directly coupled to Fab' via an SIAB group.

^b Effective protein concentration in ng/ml.

10 ^c The amount of protein/mL required to generate a response for calibrator F comparable to that generated by a commercial sample e.g. CXMB-136 in Table 3.

The more hydrophobic species of the directly coupled conjugate are effective at almost half the protein

15 concentration compared to the less hydrophobic species. These results suggest that the proportion of the ALP and Fab' polypeptide constituents are different in ALP-SIAB-Fab' compared to ALP-E3-Fab'. The relatively small differences in the effective protein concentration of
20 ALP-E3-Fab' before and after purification over Octyl-Sepharose® suggests there are similar proportions of the two protein constituents in the complex.

EXAMPLE 10

Coupling of ALP-SH to Fab'-Dendrimer

25 Fab' was coupled to NIA-activated E2 by a procedure similar to that described in Example 4, except that an Fab' solution (2.6 mg/ml in pH 6.0 buffer) was used for coupling. The reaction product was Fab'-SCH₂COHN-E2-NHCOC₂H₅I (Fab'-E2). Fab'-E2 contained 2.5 moles of
30 reactive iodoacetyl groups per mole of protein.

ALP-SH was then coupled to Fab'-E2 by incubating a 1.1 ml mixture of ALP-SH (2.8 mg) with 6.6 mg Fab'-E2 as described in Example 7. The reaction product (termed Fab'-E2-ALP) was purified by gel filtration on AcA-34.

35 The Fab'-E2-ALP product was purified over an AcA-34 column as described in Example 9. Fractions of 2 ml were

- 42 -

collected and the A_{280} of each fraction was measured. Based on the A_{280} data, there was a relatively broad column profile. Different column fractions were pooled into 2 groups and the polypeptide-dendrimer complex in 5 each pool was used as an indicator in a Stratus® CKMB assay as described in Example 3. The fluorescence response of each of the complexes is shown in Table 5.

Table 5.

Fluorescence response of Fab'-E2-ALP Complexes

10	Fluorescence Response (mV/min)	Cal A	Cal B	Cal F
	PoolA (#40-47 ^a)	519	538	1887
	PoolB (#49-51)	130	193	2824

^a Column fraction number.

15

EXAMPLE 11

Ratio of ALP to Fab' in Polypeptide-Dendrimer Complexes

The relative proportions of ALP and Fab' were determined in conjugates prepared by direct coupling through an SIAB group and complexes prepared by 20 sequential coupling to a dendrimer. For this purpose, Fluorescein and BODIPY (Molecular Probes, Eugene, OR), two fluorescent labels having different spectral characteristics, were used to label ALP and $F(ab')_2$, respectively, under mild reaction conditions known in the art. Fluorescein-containing species absorb at 495 nm and emit at 520 nm whereas BODIPY-containing species absorb 25 at 580 nm and emit at 590 nm. The immunological activity of Fab' and the enzymatic activity of ALP were not affected by this treatment. The labeled proteins then 30 were used to prepare ALP-E2-Fab' as described in Example 8 and an ALP-SIAB-Fab' directly coupled conjugate.

The product of each reaction was applied to an AcA-34 column and eluted with Tris buffer (Example 9). Column

- 43 -

fractions containing polypeptide-dendrimer complex or directly coupled conjugate were collected and pooled. Each pool then was used as an indicator in a CKMB assay as described in Example 3. Those pooled ALP-SIAB-Fab' 5 fractions that were effective as indicators showed a range of polypeptide-dendrimer molecular weights from about 180,000 daltons to about 600,000 daltons, while those pooled ALP-E2-Fab' fractions that were effective as indicators showed molecular weights ranging from about 10 160,000 daltons to about 440,000 daltons.

The fluorescence originating from ALP and Fab' in each of the pools was measured in a fluorometer by setting appropriate wave lengths for excitation and emission. These measurements suggested that the ALP-SIAB-Fab' 15 complex had a 1:6 ratio of ALP:Fab' whereas the ALP-E2-Fab' complex had a 1:3 ratio of ALP:Fab'. A higher amount of ALP per Fab' in ALP-E2-Fab' may provide an amplification of the fluorescence signal compared to ALP-SIAB-Fab'.

20

EXAMPLE 12

Sequential Coupling of Polypeptides
to Half-Generation Dendrimers

This example teaches that a half-generation carboxyl-terminated dendrimer can be sequentially coupled to two 25 different polypeptides.

A solution of the half-generation ethylenediamine core dendrimer ($G1\frac{1}{2}$ -COOH), free acid (34 mg; 16 μ M), in 0.5 mL of 80% aqueous DMF was mixed with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (390 mg; 30 2mM; EDC) and N-hydroxysuccinimide (230 mg; 2 mM). After stirring at ambient temperature for 5 hours or for 16 hours at 4°C, the reaction mixture was mixed with 5 mL ethyl acetate. A semi-solid material that separated out was macerated with isopropanol (3X5 mL). A white fluffy

- 44 -

solid was obtained after centrifugation (1000 rpm for 5 min) of the last isopropanol wash. The residue was dissolved in 0.5 mL water and N-hydroxysuccinimidyl ester concentration was determined by measuring the change in 5 A_{260} on addition of a 1% ethylenediamine solution to a small aliquot of the product diluted in 100 mM phosphate, pH 7.0. The reaction product was an activated half-generation dendrimer containing N-hydroxysuccinimidyl ester groups on substantially all of the dendrimer 10 termini. A sixth half-generation ethylenediamine dendrimer solution ($G(5\frac{1}{2})$ -COOH) was incubated with NHS and EDC under the same conditions as described above.

Within 1 hour after preparation of the active ester solution in water, a 200-500 fold molar excess of aqueous 15 solution of each activated ester dendrimer was reacted with ALP (3.4 mg/ml) at pH 7.0 in a refrigerator for 16 hours, to form the polypeptide-dendrimer complexes ALP- $G(1\frac{1}{2})$ and ALP- $G(5\frac{1}{2})$. Epsilon amino groups of lysine residues of ALP serve as the reactive moieties under 20 these conditions.

The coupling efficiency of each reaction was estimated by incubating an aliquot of the ALP/activated dendrimer mixture with an excess of ethylenediamine for 16 hours at 4°C. In addition, the ALP/ $G(1\frac{1}{2})$ -COOH activated dendrimer 25 mixture was incubated with 2-aminoethanethiol at pH 8.0. The number of amino or thiol groups (from ethylenediamine or 2-aminoethanethiol, respectively) incorporated into ALP- $G(1\frac{1}{2})$ or ALP- $G(5\frac{1}{2})$ was determined by titration with fluorescamine or dithiodipyridine (Example 4). Aminated 30 and thiolated ALP/dendrimer complexes were used as indicators on a blank paper tab as described in Example 6. The results of these experiments are shown in Table 6.

- 45 -

Table 6.
Number of Incorporated Reactive Groups and Fluorescence Response of ALP-Half Generation Dendrimer Complexes

	Complex	NH ₂ Groups/ Dendrimer	SH Groups/ Dendrimer	Fluorescence Response (mV/min) ^a
5	ALP	44 ^b	-- ^c	77
	ALP-G(1½)-NH ₂	127	--	8,004
	ALP-G(1½)-SH	--	43	6,454
	ALP-G(5½)-NH ₂	547	--	>50,000 ^c

10 ^a 250 ng protein/ml indicator solution on blank paper tabs in a Stratus® II

^b Expected value is 53, based on M. Fosset, et al., Intestinal Alkaline Phosphatase: Physical properties and quaternary structure. Biochemistry:13 pp 1783-1788 (1974).

15 ^c Fluorescence response was greater than the maximum reading on the Stratus® II instrument.

^d -- = Not applicable.

The high level of non-specific binding (as shown by the fluorescence response data) indicates that there were a

20 large number of uncoupled dendrimer termini remained in the ALP-dendrimer complexes.

ALP3 (ALP modified by periodate treatment as in Example 5) was incubated for 30 minutes as described above, using NHS-activated G(1½)-COOH dendrimer at molar ratios of

25 20:1, 100:1, and 500:1 dendrimer:ALP3. Coupling efficiency in each reaction was tested by incubating the ALP-dendrimer reaction product with 2-aminoethanethiol and determining the number of incorporated SH groups as described above. Each thiolated product was then used as

30 an indicator on a blank paper tab in a CKMB assay and the fluorescence response was recorded. The results are shown in Table 7 below. The data indicate that as the molar challenge ratio of activated dendrimer:ALP increases, the number of incorporated SH groups increases

35 as well as the level of non-specific binding.

- 46 -

Table 7

Challenge ratio ^a	SH Groups/ Dendrimer ^b	Non-specific binding ^c (mV/Min)
0	0	77
5 20	1.4	77
100	3.0	734
500	5.3	4,756

^a Ratio of activated dendrimer: ALP (mole/mole) in reaction mix.

^b Number of 2-aminoethanethiol SH groups incorporated/dendrimer determined by titration with dithiodipyridine.

^c Fluorescence response using 250 ng of complex (protein basis)/ml indicator.

ALP3 was reacted as described above with NHS-activated G(1½)-COOH dendrimer at a challenge ratio of 50:1 activated dendrimer:ALP3. The ALP:dendrimer product was then reacted as described above with 2-aminoethanethiol. The resulting product, ALP-G(1½)-SH, contained 2.6 reactive sulfhydryls.

Fab' was activated with 1,4-butanediol diglycidyl ether (BDE), a homobifunctional cross-linker by mixing 0.16 ml of BDE (97 mM) with Fab' (0.9 mg/ml, 50 µM) and incubating at 4° C, for 24 hours in 100 mM phosphate, 5.0 mM EDTA, pH 6.0. The reaction product was shown to contain 0.5 moles of epoxide reactive moieties per mole of protein. The epoxy groups were incorporated on the sulfhydryl groups in the Fab' hinge region. ALP-G(1½)-SH and Fab'-epoxide were then coupled for 24 hours as described in Example 7. The ALP-G(1½)-Fab' polypeptide-dendrimer complex was used as an indicator in a CKMB assay as described in Example 3. The fluorescence response data are shown in Table 8.

- 47 -

Table 8.
ALP-G(1½)-Fab' as Indicator in CKMB Assay

	Fluorescence Response (mV/min)	
	Cal A ^a	Cal F
5 CXMB-136	113	7,696
ALP-G(1½)-Fab'	8,053	10,623

^a Calibrator A is 0.0 ng/mL; Calibrator F is 131.6 ng/mL

EXAMPLE 13

Sequential Coupling of CHO- and SH-Polypeptides

10 to COOH- and COCH₂Br-Termini

The free acid form of G(1½)-COOH (20 mg, 9.2 µM) dissolved in 1.0 mL of water/dioxan/DMF (1:2:2 v/v) was activated with N, N, N',N'-tetramethyl(succinimido)uronium tetrafluoroborate (TSTU) (69 mg, 230 µM) in the presence of N, N-diisopropylethylamine (89 mg, 690 µM, DPA). After one hour at ambient temperature, the volatile organics were removed under reduced pressure and a solid residue obtained was washed with ethyl acetate (3X5 mL). The ethyl acetate insoluble material was dried in vacuo and dissolved in 0.5 mL water. The concentration of active ester in the aqueous solution was determined by titration with ethylenediamine as described in Example 12; the data confirmed that substantially all of the dendrimer termini had been esterified with N-hydroxysuccinimidyl groups.

ALP3 was reacted with NHS-activated G(1½) at pH 7.0 for 30 minutes in an ice bath as described in Example 12. The reaction mixture then was incubated with 1.5 volumes of 0.2 M hexamethylenediamine (HMD) at pH 9.0 for 2 hours, which incorporated reactive amino groups at dendrimer termini that had not been coupled to ALP.

The product was separated from non-protein impurities by ultrafiltration using pH 7.0 phosphate buffer and the number of amino groups estimated by titration with

- 48 -

fluorescamine. The titration data showed that there were about 31 amino groups. Unreacted ALP3 is expected to have about 55 amino groups and unreacted NHS-activated G(1½) is expected to have about 12 amino group termini.

5 The difference between the observed number of reactive amino groups (31) and the number expected in the presence of an equimolar ALP-dendrimer coupling (66) suggested that ALP3 molecules had been coupled to NHS-activated termini on G(1½)-COOH dendrimers. However, it is

10 unlikely that substantially all of the NHS-activated dendrimer termini were coupled to an ALP molecule.

Most of the difference between the observed and expected number of reactive amino groups in the ALP-dendrimer complex likely is due to other reasons. One

15 possible explanation, formation of an $(ALP)_n\text{-}G(1\frac{1}{2})$ complex having greater than about 2 ALP3 molecules per dendrimer was ruled out from a size exclusion column profile of the polypeptide-dendrimer complex. Uncoupled NHS-activated carboxyl termini in ALP-G(1½) may decompose

20 to a form that does not react with HMD, or both amino groups of HMD may each react with an NHS-activated terminus. The titration calculations assume that only one amino group of HMD is reactive; if both HMD amino groups are reactive, the calculations underestimate the

25 actual number of NHS termini remaining uncoupled to an ALP molecule.

A heterobifunctional cross-linking agent, 6-bromoacetamido-hexylamine ($\text{BrCH}_2\text{CONH(CH}_2)_6\text{NH}_2$; BAHA), was synthesized as the trifluoroacetate salt. A solution of

30 N-hydroxysuccinimidyl bromoacetate (3.5 g/35 mL THF) was mixed with a solution of the free base prepared from N-Boc-1,6-diaminohexane hydrochloride (3.5 gm/20 mL methanol). After two hours at ambient temperature, the methanol-THF solution was evaporated to dryness on a

35 rotary evaporator. Without purification, the white

- 49 -

residue obtained was dissolved in 50 mL dichloromethane and 30 mL trifluoroacetic acid. The resulting clear solution was stirred at ambient temperature for two hours. The reaction mixture was evaporated to dryness on 5 a rotary evaporator using a bath at 30°C. The white oil obtained after evaporation was crystallized from isopropanol to give 0.75 g of a white crystalline product, mp 121°C (BAHA).

ALP3 was reacted separately with NHS-activated G(1½)-COOH and G(2½)-COOH (activated using TSTU as described above). The crude reaction mixtures (1.1 mL) were each mixed with a solution of BAHA (20 mg/0.4 mL isopropanol) and incubated at 4°C for 16 hours. Non-protein components were removed by ultrafiltration using 100 mM phosphate, 1.0 mM MgCl₂, pH 7.0.

The resulting ALP-G(1½) and ALP-G(2½) complexes were titrated with 2-aminoethanethiol as described in Example 4 except that 2-aminoethanethiol was used in place of DTE. The titration results indicated that 3.9 and 4.8 20 reactive bromoacetamido groups, respectively, had been incorporated onto dendrimer termini uncoupled to ALP. The number of bromoacetamido groups expected if all uncoupled termini had reacted with BAHA was about 11 for ALP-G(1½) and 23 for ALP-G(2½), assuming an equimolar 25 coupling of ALP with G(1½)-COOH and with G(2½)-COOH.

ALP-G(4½)-COCH₂Br (containing five 2-aminoethanethiol-reactive groups per mole of the protein) was prepared as described for ALP-G(1½)-COCH₂Br. The fluorescence response on blank paper tabs of ALP-G(1½), ALP-G(2½) and 30 ALP-G(4½) indicated that these three complexes had fluorescence response rates of ≤ 100 mV/min. In contrast, the non-specific binding of full generation amino-terminated dendrimer-ALP complexes increased as the generation number increased (Table 3).

- 50 -

ALP-G(1½)-COCH₂Br and ALP-G(4½)-COCH₂Br were reacted with Fab' for 24 hours at pH 7.6 as described in Example 8 for ALP-Iodoacetyl Dendrimer complexes. The polypeptide-dendrimer complexes ALP-G(1½)-Fab' and ALP-G(4½)-Fab' were evaluated as indicators in a specific binding assay as described in Example 3. The results are shown in Table 9.

Table 9.
Fluorescence Response of Half Generation
Dendrimer Complexes

Indicator	Cal A	Cal B	Cal F
CXMB-139 ^a	104	328	7698
ALP-G(1½)-Fab' ^b	48	320	7083
ALP-G(4½)-Fab' ^c	86	356	8454

^a 590 ng protein/ml indicator.

^b 740 ng protein/ml indicator.

^c 434 ng protein/ml indicator.

The performance of these complexes as indicators in a specific binding assay is similar to that of a directly conjugated indicator (CXMB-139) currently used for the same type of assay. Furthermore, the amount of protein applied to the tab for ALP-G(4½)-Fab' was about 25% less than the amount required for CXMB-139.

To the extent not already indicated, it will be understood by those of ordinary skill in the art that any one of the various specific embodiments herein described and illustrated may be further modified to incorporate features shown in other of the specific embodiments.

The foregoing detailed description has been provided for a better understanding of the invention only and no unnecessary limitation should be understood therefrom as some modifications will be apparent to those skilled in the art without deviating from the spirit and scope of the appended claims.

- 51 -

WHAT IS CLAIMED IS:

1. A dendrimer-polypeptide complex comprising a dendrimer having a plurality of termini, said dendrimer sequentially coupled via at least one of said termini to a first polypeptide and via at least a different one of said termini to a second polypeptide, said first and second polypeptides of said complex exhibiting first and second defined biological activities, respectively.
2. The composition of claim 1, wherein a fraction of said termini are uncoupled and substantially all of said uncoupled termini are blocked.
3. The composition of claim 1, wherein said dendrimer is selected from the group consisting of a first, a second, a third, a fourth and a fifth generation ethylenediamine core dendrimer.
4. The composition of claim 1, wherein said dendrimer is selected from the group consisting of a first, a second, a third, a fourth and a fifth half-generation ethylenediamine core dendrimer.
5. The composition of claim 1, wherein one of said defined biological activities comprises enzymatic catalysis.
6. The composition of claim 5, wherein said enzymatic catalysis comprises formation of a fluorescent, colorimetric, chemiluminescent, phosphorescent, radiometric or hybridized product after contact with a substrate.

- 52 -

7. The composition of claim 6, wherein said polypeptide exhibiting said enzymatic catalysis is selected from the group consisting of alkaline phosphatase, β -galactosidase, glucose oxidase, 5 peroxidase, urease, catalase, adenosine deaminase, glycosidase, protease, esterase, DNase, RNase and acetylcholinesterase.
8. The composition of claim 1, wherein one of said defined biological activities comprises specific binding 10 to an analyte, or a receptor for said analyte.
9. The composition of claim 8, wherein said polypeptide exhibiting said specific binding biological activity is selected from the group consisting of an antibody or antibody fragment having binding specificity 15 for creatine kinase isozyme MB, carbonic anhydrase 3, troponin I, myoglobin, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone and ferritin.
10. The composition of claim 1, wherein said first 20 defined biological activity comprises enzymatic catalysis and said second defined biological activity comprises specific binding to an analyte, or receptor for said analyte.
11. A dendrimer-polypeptide complex comprising a 25 dendrimer coupled to a first polypeptide, said polypeptide of said complex exhibiting a first defined biological activity, said dendrimer having at least one activated terminus effective for subsequently coupling a second polypeptide possessing a second defined biological 30 activity thereto, wherein said first and second

- 53 -

polypeptides exhibit said respective defined biological activities following said subsequent coupling.

12. The composition of claim 11, wherein said first defined biological activity comprises enzymatic 5 catalysis.

13. The composition of claim 12, wherein said first defined biological activity comprises formation of a fluorescent, colorimetric, chemiluminescent, phosphorescent, radiometric or hybridized product after 10 contact with a substrate.

14. The composition of claim 13, wherein said first polypeptide is selected from the group consisting of alkaline phosphatase, β -galactosidase, glucose oxidase, peroxidase, urease, catalase, adenosine deaminase, 15 glycosidase, protease, esterase, DNase, RNase and acetylcholinesterase.

15. A method of making a dendrimer/polypeptide complex, comprising the steps of:

a) providing a dendrimer comprising a plurality of 20 activated termini;

b) providing a first polypeptide having at least one reactive moiety, said first polypeptide possessing a first defined biological activity;

c) coupling said first polypeptide via said reactive 25 moiety to one of said activated dendrimer termini to form a dendrimer/polypeptide complex exhibiting said first defined biological activity, said complex effective for subsequently coupling a second polypeptide possessing a second defined biological activity to said dendrimer, 30 wherein said first and second polypeptides exhibit a said

- 54 -

respective defined biological activity following said subsequent coupling.

16. The method of claim 15, wherein said dendrimer is selected from the group consisting of a first, a second, 5 a third, a fourth and a fifth generation ethylenediamine core dendrimer.

17. The method of claim 16, wherein said reactive moiety comprises a sulfhydryl group and said plurality of activated termini comprise a plurality of iodoacetyl 10 groups.

18. The method of claim 15, wherein said dendrimer is selected from the group consisting of a first, a second, a third, a fourth and a fifth half-generation ethylenediamine core dendrimer.

15 19. The method of claim 18, wherein said reactive moiety comprises an amino group and said plurality of activated termini comprise a plurality of N-hydroxysuccinimidyl groups.

20. The method of claim 15, further comprising the 20 steps of:

- a) providing a second polypeptide having at least one reactive moiety, said second polypeptide possessing a second defined biological activity;
- b) coupling said second polypeptide reactive moiety 25 to one of said activated termini to form a dendrimer:two-polypeptide complex, said first and second polypeptides of said complex exhibiting said first and second defined biological activities, respectively.

- 55 -

21. The method of claim 20, wherein said first polypeptide reactive moiety comprises a sulfhydryl group, second polypeptide reactive moiety comprises a sulfhydryl group and said plurality of activated termini are 5 selected from the group consisting of a plurality of iodoacetyl, bromoacetyl, chloroacetyl, epoxy and maleimidyl groups.

22. The method of claim 15, wherein at least one of said activated termini in said complex is uncoupled, said 10 method further comprising the steps of:

- a) activating said at least one uncoupled terminus of said dendrimer/polypeptide complex with a second activating group to form a second activated terminus;
- b) providing a second polypeptide having a reactive 15 moiety, said second polypeptide possessing a second defined biological activity; and
- c) coupling said second polypeptide reactive moiety to said second activated terminus to form a dendrimer:two-polypeptide complex, said first and second 20 polypeptides of said complex exhibiting said first and second defined biological activities, respectively.

23. The method of claim 22, wherein said first polypeptide reactive moiety comprises an amino group, said second polypeptide reactive moiety comprises a 25 sulfhydryl group, said plurality of activated termini comprise a plurality of N-hydroxysuccinimidyl groups and said second activated terminus is selected from the group consisting of a bromoacetyl, iodoacetyl, chloroacetyl, epoxy and maleimidyl group.

30 24. A method for conducting a specific binding assay to determine the concentration or presence of an analyte in a sample, comprising the steps of:

- 56 -

- a) immobilizing an effective amount of a specific binding assay reagent with specificity for said analyte, or for a receptor of said analyte, to a solid phase;
- b) applying said sample under binding conditions to 5 said solid phase;
- c) applying a selected amount of an indicator comprising a dendrimer having a plurality of termini, said dendrimer coupled via at least a first of said termini to a first polypeptide and via at least a second 10 of said termini to a second polypeptide, one of said polypeptides comprising a label and the other of said polypeptides comprising a specific binding receptor for said analyte, or for a receptor of said analyte;
- d) determining the amount of said dendrimer- 15 polypeptide indicator bound to said solid phase; and
- e) correlating said amount of said indicator with the concentration or presence of said analyte, or receptor of said analyte, in said sample.

25. The method of claim 24, wherein a fraction of said 20 termini are uncoupled and substantially all of said uncoupled termini are blocked.

26. A method for conducting a specific binding assay to determine the concentration or presence of an analyte in a sample, comprising the steps of:

- 25 a) providing a reagent solution comprising an effective amount of a specific binding assay reagent with specificity for said analyte, or for a receptor of said analyte;
- b) adding said sample under specific binding 30 conditions to said reagent solution to form an assay solution;
- c) adding an effective amount of said assay solution to a solid phase under conditions effecting





- 57 -

immobilization of said reagent on a delimited area of said solid phase;


- d) applying to said delimited area an indicator comprising a dendrimer having a plurality of termini,
- 5 said dendrimer coupled via at least a first of said termini to a first polypeptide and via at least a second of said termini to a second polypeptide, one of said polypeptides comprising a label and the other of said polypeptides comprising a specific binding receptor for
- 10 said analyte, or for a receptor of said analyte;
- e) determining the amount of said dendrimer-polypeptide indicator bound to said solid phase; and
- f) correlating said amount of said indicator with the concentration or presence of said analyte, or receptor of
- 15 said analyte, in said sample.

27. The method of claim 26, wherein a fraction of said termini are uncoupled and substantially all of said uncoupled termini are blocked.

1/2

FIG1: ALP-E1-FAB^{*}FIG 2: ALP-E2-FAB^{*}FIG 3: ALP-E3-FAB^{*}FIG 4: ALP-E4-FAB^{*}

2/2

FIG 5: ALP-E5-FAB⁺

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/13057

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/545 G01N33/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIOCONJUGATE CHEMISTRY, vol. 1, no. 5, 1 September 1990, pages 305-308, XP000174624 ROBERTS J C ET AL: "USING STARBURST DENDRIMERS AS LINKER MOLECULES TO RADIOLEBEL ANTIBODIES" see the whole document ---	1-27
Y	WO,A,88 01178 (DOW CHEMICAL CO) 25 February 1988 cited in the application see page 15, line 35 - page 16, line 3 see page 20, line 17 - line 24 see page 26, line 23 see page 30, line 5 - line 16 ---	1-27 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- '&' document member of the same patent family

1

Date of the actual completion of the international search

5 December 1996

Date of mailing of the international search report

17.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Cartagena y Abella, P

INTERNATIONAL SEARCH REPORT

International Application No
PL./US 96/13057

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,94 19693 (BAXTER DIAGNOSTICS INC) 1 September 1994 cited in the application see abstract see page 4, line 25 - page 5, line 7 ---	1-27
P,A	WO,A,95 28641 (DADE INT INC) 26 October 1995 cited in the application ---	
P,A	WO,A,95 27902 (DADE INT INC) 19 October 1995 cited in the application ---	
P,X	ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 211, no. 1-2, 24 - 28 March 1996, NEW ORLEANS, page BIOT 193 XP002020332 P. SINGH: "Coupling of multiple proteins to starburst dendrimers." see the whole document -----	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/13057

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-8801178	25-02-88	AU-B-	609051	26-04-91
		AU-A-	7715987	03-03-88
		AU-B-	638153	17-06-93
		AU-A-	8139191	03-10-91
		CA-A-	1316456	20-04-93
		CA-A-	1316524	20-04-93
		CA-A-	1316364	20-04-93
		DE-A-	3786000	01-07-93
		EP-A-	0271180	15-06-88
		ES-T-	2054678	16-08-94
		HK-A-	54396	03-04-96
		HU-B-	209252	28-04-94
		IE-B-	61356	02-11-94
		JP-A-	6220190	09-08-94
		JP-A-	6219966	09-08-94
		JP-B-	7108860	22-11-95
		JP-A-	6009778	18-01-94
		JP-B-	7057735	21-06-95
		JP-T-	63502350	08-09-88
		JP-B-	7057736	21-06-95
		JP-T-	63501876	28-07-88
		JP-B-	7002840	18-01-95
		JP-T-	63501878	28-07-88
		NO-B-	176306	05-12-94
		US-A-	5527524	18-06-96
		WO-A-	8801179	25-02-88
		WO-A-	8801180	25-02-88
		WO-A-	9524221	14-09-95
		US-A-	5560929	01-10-96
		US-A-	5338532	16-08-94
-----	-----	-----	-----	-----
WO-A-9419693	01-09-94	AU-A-	6267794	14-09-94
		CA-A-	2133967	01-09-94
		EP-A-	0637385	08-02-95
		JP-T-	7506195	06-07-95
		ZA-A-	9401084	17-08-95
-----	-----	-----	-----	-----
WO-A-9528641	26-10-95	AU-A-	2243195	10-11-95
		CA-A-	2164939	26-10-95
		EP-A-	0704058	03-04-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL, /US 96/13057

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9527902	19-10-95	AU-A- 2288995	30-10-95
		CA-A- 2164938	19-10-95
		EP-A- 0702792	27-03-96